Colby Pharmaceutical Acquires Othera Pharmaceuticals
9/19/2012 10:08:08 AM
More...
|
Othera Pharmaceuticals Reports Preserved Visual Function in Clinical Trial of OT-551 Eye Drop Treatment for Advanced Dry AMD
3/23/2010 12:45:58 PM
More...
|
Othera Pharmaceuticals Announces Positive Interim Phase 2 Results of OT-551 Eye Drop Treatment for Dry AMD
4/8/2009 12:47:41 PM
More...
|
Othera Pharmaceuticals Announces First U.S. Patent Issued On New Class of Compounds to Treat AMD and Other Ophthalmic Diseases
10/28/2008 8:36:32 AM
More...
|
Othera Pharmaceuticals Initiates Phase I/II Clinical Trial of OT-730 In Ocular Hypertension and Glaucoma
9/15/2008 8:39:56 AM
More...
|
Othera Pharmaceuticals Files IND Application for OT-730 in Glaucoma
7/30/2008 9:41:26 AM
More...
|
Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer
10/2/2007 10:20:37 AM
More...
|
Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer
10/1/2007 8:27:27 AM
More...
|
Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
9/26/2007 12:52:16 PM
More...
|
Othera Pharmaceuticals and the National Eye Institute Reach Target Enrollment in Dry AMD Clinical Trial with OT-551 Eye Drops
6/18/2007 2:23:48 PM
More...
|
|